Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
Pharmacodynamic Models: Additive and Proportional Drug Effect Model01:09

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model01:29

Pharmacodynamic Models: Direct Effect Model and Indirect Response Model

Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Minimum noninferiority dose for phase I clinical trials with immunotherapy.

Biometrics·2026
Same author

Identifying Meaningful Patient Savings on Generics: Direct-to-Consumer Prices Versus Commercial Insurance Cost Sharing.

Annals of internal medicine·2026
Same author

Chemotherapy Declination Among Patients With Early-Stage Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer and High Oncotype DX Recurrence Scores.

JCO oncology practice·2026
Same author

Patient Retreat in Dose Escalation for Phase I Clinical Trials With Rare Diseases.

Statistics in medicine·2026
Same author

Wasserstein GAN-based estimation for conditional distribution function with current status data.

Lifetime data analysis·2026
Same author

Specialty Oral Anticancer Prescription Fill Rates After Medicare Part D Cost-Sharing Changes in 2024.

JAMA·2025

Related Experiment Video

Updated: Jun 14, 2026

The Adjuvant Efficacy of Angong Niuhuang Pill in the Treatment of Viral Encephalitis: A Meta-Analysis of Randomized Controlled Trials
08:36

The Adjuvant Efficacy of Angong Niuhuang Pill in the Treatment of Viral Encephalitis: A Meta-Analysis of Randomized Controlled Trials

Published on: April 19, 2024

Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity.

Xiudong Lei1, Ying Yuan, Guosheng Yin

  • 1Department of Biostatistics, Unit 1411, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77230, USA. xiulei@mdanderson.org

Lifetime Data Analysis
|April 6, 2010
PubMed
Summary
This summary is machine-generated.

This study introduces a Bayesian adaptive randomization method for oncology clinical trials, balancing early toxicity detection with long-term efficacy assessment for better treatment selection.

Related Experiment Videos

Last Updated: Jun 14, 2026

The Adjuvant Efficacy of Angong Niuhuang Pill in the Treatment of Viral Encephalitis: A Meta-Analysis of Randomized Controlled Trials
08:36

The Adjuvant Efficacy of Angong Niuhuang Pill in the Treatment of Viral Encephalitis: A Meta-Analysis of Randomized Controlled Trials

Published on: April 19, 2024

Area of Science:

  • Oncology
  • Biostatistics
  • Clinical Trial Design

Background:

  • Chemotherapy in oncology presents a challenge where toxicity is observed early, but efficacy (tumor shrinkage) takes longer to assess.
  • Traditional clinical trial designs may not optimally balance the timely evaluation of both toxicity and efficacy.

Purpose of the Study:

  • To propose a novel Bayesian adaptive randomization procedure for Phase II oncology clinical trials.
  • To integrate both efficacy (time-to-event) and toxicity (binary) outcomes within a unified statistical framework.
  • To allow patient covariates to influence randomization probabilities for personalized treatment allocation.

Main Methods:

  • A Bayesian adaptive randomization procedure modeling bivariate outcomes (efficacy and toxicity) with shared random effects.
  • Incorporation of patient-specific covariates into the randomization probability.
  • Development of early stopping rules for toxicity and futility, and criteria for recommending superior treatments.

Main Results:

  • Extensive simulation studies were conducted under various scenarios to evaluate the proposed method's performance.
  • The method was compared against existing Bayesian adaptive randomization procedures.
  • The simulations demonstrated the procedure's ability to effectively balance early toxicity monitoring and long-term efficacy evaluation.

Conclusions:

  • The proposed Bayesian adaptive randomization method offers a robust approach for Phase II oncology trials.
  • This method enhances the efficiency of clinical trials by simultaneously considering critical efficacy and toxicity endpoints.
  • The adaptive design allows for more informed treatment selection and potential early termination of ineffective or harmful arms.